HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Herbalife Forecasts Smoother Sailing Following FTC Settlement Bumps

This article was originally published in The Rose Sheet

Executive Summary

Despite a first-quarter slump, changes being implemented in Herbalife's North American operations, some required by under is 2016 settlement an FTC investigation, point to better results for the rest of 2017, the nutrition and weight loss supplement direct seller says.

You may also be interested in...



Supplement Sector Settlements Frame FTC Guidance On Direct Sellers' Compensation Claims

Guidance notes settlements Herbalife and Vemma Nutrition made in 2016 as examples of its enforcement policies. FTC prohibition against misleading claims extends to requiring direct sellers to base claims of distributors' compensation on sales to consumers, not on measures such recruiting more distributors.

Warnings, Earnings, Racing: Health And Wellness Industry News

Armada Nutrition response on 483 observations inadequate; Herbalife ‘entering new chapter’; Mannatech turns around from year-ago loss; and Prevagen goes racing.

Warnings, Nutrition Facts Deadline: Health And Wellness Industry News

Summit Nutritionals off track with 'made in USA' labeling; Perfect Posh cosmetic line makes drug claims; covert deadline extension for Nutrition Facts changes; CPSC discusses improving recalls; and more news in brief.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS109244

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel